Skip to main content

8 Result(s)

within F Lacombe Remove this filter Cancer Research Remove this filter Oncology Remove this filter

and

  1. No Access

    Article

    Harmonemia: a universal strategy for flow cytometry immunophenoty**—A European LeukemiaNet WP10 study

    F Lacombe, E Bernal, D Bloxham, S Couzens, M G D Porta, U Johansson, W Kern… in Leukemia (2016)

  2. No Access

    Article

    Immunophenoty** of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10

    The European LeukemiaNet (ELN), workpackage 10 (WP10) was designed to deal with diagnosis matters using morphology and immunophenoty**. This group aimed at establishing a consensus on the required reagents f...

    M C Béné, T Nebe, P Bettelheim, B Buldini, H Bumbea, W Kern, F Lacombe, P Lemez… in Leukemia (2011)

  3. No Access

    Article

    Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study

    An early appreciation of treatment efficacy could be very useful in acute myeloblastic leukemia (AML), and a prognostic value has been suggested for the morphological assessment of decrease in blasts during in...

    F Lacombe, C Arnoulet, M Maynadié, E Lippert, I Luquet, A Pigneux, N Vey… in Leukemia (2009)

  4. No Access

    Article

    Discriminant function analysis as decision support system for the diagnosis of acute leukemia with a minimal four color screening panel and multiparameter flow cytometry immunophenoty**

    Despite several recommendations for standardization of multiparameter flow cytometry (MFC) the number, specificity and combinations of reagents used by diagnostic laboratories for the diagnosis and classificat...

    R Ratei, L Karawajew, F Lacombe, K Jagoda, G D Poeta, J Kraan, M De Santiago… in Leukemia (2007)

  5. No Access

    Article

    Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571

    The leukemogenic property of BCR-ABL in chronic myeloid leukemia (CML) is critically dependent on its protein tyrosine kinase activity. STI571 inhibits the BCR-ABL kinase activity, the growth and the viability...

    R Tabrizi, FX Mahon, P Cony Makhoul, V Lagarde, F Lacombe, P Berthaud, JV Melo… in Leukemia (2002)

  6. No Access

    Article

    Early transitory rise in intracellular pH leads to Bax conformation change during ceramide-induced apoptosis

    Ceramide can induce apoptosis through a caspase independent pathway. Bax has been described as able to kill cells in the absence of caspase activity, therefore we measured Bax in situ during ceramide-induced apop...

    M.A. Belaud-Rotureau, N. Leducq, F. Macouillard Poulletier de Gannes… in Apoptosis (2000)

  7. No Access

    Article

    Study of apoptosis-related responses of leukemic blast cells to in vitro anthracycline treatment

    Anthracyclines trigger an apoptotic cell death but their molecular targets are not totally explored. We investigated the apoptotic response of blast cells and lymphocytes from medullary samples of 31 de novo acut...

    M-A Belaud-Rotureau, F Durrieu, G Labroille, F Lacombe, O Fitoussi, P Agape… in Leukemia (2000)

  8. No Access

    Article

    Flow cytometry CD45 gating for immunophenoty** of acute myeloid leukemia

    A flow cytometry method has been introduced into the routine investigation of whole bone marrow samples following red blood cell lysis on the basis of a primary CD45/side scatter (SSC) gating procedure. Blast ...

    F Lacombe, F Durrieu, A Briais, P Dumain, F Belloc, E Bascans, J Reiffers… in Leukemia (1997)